KDNY Chinook Therapeutics Inc

Price (delayed)

$17.8

Market cap

$982.16M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.92

Enterprise value

$919.62M

Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook's product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined ...

Highlights
Chinook Therapeutics's EPS has soared by 67% YoY and by 15% from the previous quarter
KDNY's net income is up by 14% year-on-year and by 5% since the previous quarter
The equity has grown by 42% YoY but it has contracted by 6% from the previous quarter
The company's quick ratio fell by 13% YoY but it rose by 3.1% QoQ

Key stats

What are the main financial stats of KDNY
Market
Shares outstanding
55.18M
Market cap
$982.16M
Enterprise value
$919.62M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.29
Price to sales (P/S)
19.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.04
Earnings
Revenue
$53.97M
EBIT
-$95.31M
EBITDA
-$84.57M
Free cash flow
-$101.04M
Per share
EPS
-$1.92
Free cash flow per share
-$1.73
Book value per share
$7.77
Revenue per share
$0.93
TBVPS
$8.67
Balance sheet
Total assets
$531.27M
Total liabilities
$104.48M
Debt
$43.04M
Equity
$426.8M
Working capital
$249.21M
Liquidity
Debt to equity
0.1
Current ratio
7.82
Quick ratio
7.69
Net debt/EBITDA
0.74
Margins
EBITDA margin
-156.7%
Gross margin
100%
Net margin
-180.5%
Operating margin
-171.8%
Efficiency
Return on assets
-20.7%
Return on equity
-26.9%
Return on invested capital
-30.4%
Return on capital employed
-19.3%
Return on sales
-176.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KDNY stock price

How has the Chinook Therapeutics stock price performed over time
Intraday
-1.06%
1 week
-4.04%
1 month
15.43%
1 year
25%
YTD
9.14%
QTD
8.8%

Financial performance

How have Chinook Therapeutics's revenue and profit performed over time
Revenue
$53.97M
Gross profit
$53.97M
Operating income
-$92.7M
Net income
-$97.41M
Gross margin
100%
Net margin
-180.5%
The operating margin has soared by 98% YoY and by 10% from the previous quarter
Chinook Therapeutics's net margin has surged by 98% YoY and by 9% QoQ
KDNY's net income is up by 14% year-on-year and by 5% since the previous quarter
Chinook Therapeutics's operating income has increased by 6% from the previous quarter but it has decreased by 3.8% YoY

Growth

What is Chinook Therapeutics's growth rate over time

Valuation

What is Chinook Therapeutics stock price valuation
P/E
N/A
P/B
2.29
P/S
19.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.04
Chinook Therapeutics's EPS has soared by 67% YoY and by 15% from the previous quarter
The equity has grown by 42% YoY but it has contracted by 6% from the previous quarter
KDNY's price to book (P/B) is 16% more than its last 4 quarters average of 2.0 but 14% less than its 5-year quarterly average of 2.7
KDNY's P/S is 92% below its last 4 quarters average of 252.9 and 85% below its 5-year quarterly average of 131.4
The revenue has increased by 4.5% since the previous quarter

Efficiency

How efficient is Chinook Therapeutics business performance
Chinook Therapeutics's ROS has soared by 98% YoY and by 10% from the previous quarter
KDNY's return on equity has surged by 58% year-on-year and by 14% since the previous quarter
KDNY's ROIC has soared by 51% YoY and by 21% from the previous quarter
The return on assets has increased by 39% year-on-year and by 12% since the previous quarter

Dividends

What is KDNY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KDNY.

Financial health

How did Chinook Therapeutics financials performed over time
The total assets is up by 33% YoY but it is down by 6% QoQ
The current ratio has decreased by 14% YoY but it has increased by 4.3% from the previous quarter
Chinook Therapeutics's debt is 90% lower than its equity
The equity has grown by 42% YoY but it has contracted by 6% from the previous quarter
The debt to equity has declined by 29% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.